Santiago Arroyo Sells 4,943 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) insider Santiago Arroyo sold 4,943 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $69,646.87. Following the completion of the transaction, the insider now directly owns 69,057 shares of the company’s stock, valued at approximately $973,013.13. The trade was a 6.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Bicycle Therapeutics Price Performance

Shares of NASDAQ BCYC opened at $14.17 on Thursday. The stock has a market capitalization of $978.38 million, a P/E ratio of -4.31 and a beta of 0.92. Bicycle Therapeutics plc has a one year low of $12.17 and a one year high of $28.67. The firm’s 50 day simple moving average is $19.09 and its two-hundred day simple moving average is $21.82.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.04. The company had revenue of $2.68 million for the quarter, compared to analyst estimates of $6.82 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The firm’s quarterly revenue was down 50.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.26) EPS. As a group, equities analysts expect that Bicycle Therapeutics plc will post -3.05 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. JMP Securities lowered their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a research report on Wednesday, December 18th. HC Wainwright dropped their price target on Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating for the company in a research report on Monday, December 16th. Needham & Company LLC restated a “buy” rating and issued a $38.00 price objective on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. Stephens started coverage on shares of Bicycle Therapeutics in a research report on Friday, November 8th. They set an “equal weight” rating and a $25.00 target price for the company. Finally, B. Riley decreased their price target on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Bicycle Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $35.25.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Assetmark Inc. bought a new position in Bicycle Therapeutics during the 3rd quarter worth approximately $34,000. GAMMA Investing LLC boosted its stake in shares of Bicycle Therapeutics by 105.1% during the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after purchasing an additional 1,038 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of Bicycle Therapeutics by 69.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock worth $162,000 after purchasing an additional 2,918 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock worth $191,000 after buying an additional 1,782 shares during the period. Finally, XTX Topco Ltd bought a new stake in Bicycle Therapeutics during the 2nd quarter valued at $206,000. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.